Research Article Details
| Article ID: | A22389 |
| PMID: | 24626737 |
| Source: | Food Funct |
| Title: | A diet formula of Puerariae radix, Lycium barbarum, Crataegus pinnatifida, and Polygonati rhizoma alleviates insulin resistance and hepatic steatosis in CD-1 mice and HepG2 cells. |
| Abstract: | According to the principles of traditional Chinese medicine, medicinal and edible herbs exhibit holistic effects through their actions on multiple target organs. Four herbs, Puerariae radix, Lycium barbarum, Crataegus pinnatifida, and Polygonati rhizoma, were selected and combined to create a new herbal formula (PLCP). The protective effects of both the aqueous extract (AE) and ethanol extract (EE) of PLCP against insulin resistance (IR) and non-alcoholic fatty liver disease (NAFLD) were evaluated in both high fat and high fructose diet-fed mice. Active fractions and constituents were screened in HepG2 cells with IR or an over-accumulation of triglycerides, and were further identified by high-performance liquid chromatography/electrospray ionization/mass spectrometry. The results indicate that the AE did not improve (p > 0.05) glucose tolerance after three weeks, whereas EE showed a promising effect throughout the experiment. Medium and high doses of EE were found to reduce fasting blood glucose at week 9 by 21.1% and 24.4%, respectively. In addition, their efficacies for alleviating IR were comparable with that of metformin. Compared with AE, EE effectively improved hyperlipidemia, antioxidant status, and NAFLD. In contrast, metformin did not alleviate hyperlipidemia (p > 0.05) or NAFLD in the mice model. Results from the cell-based study indicate that the protective effects of EE were possibly due to the actions from puerarin, 3'-methoxypuerarin, daidzin, daidzein, and ononin. |
| DOI: | 10.1039/c3fo60524h |
| Strategy ID | Therapy Strategy | Synonyms | Therapy Targets | Therapy Drugs | |
|---|---|---|---|---|---|
| S01 | Improve insulin resistance | insulin sensitizer; insulin resistance; glucose tolerance | Biguanide: increases 5-AMP activated protein kinase signaling; SGLT-2 inhibitor; Thiazalidinedione: selective PPAR-γ agonists; GLP-1 agonist | Metformin; Empagliflozin; Canagliflozin; Rosiglitazone; Pioglitazone; Liraglutide | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name | |
|---|---|---|---|---|---|---|---|
| T10 | Caspase-1 | CASP1 | inhibitor | Enzyme | P29466 | CASP1_HUMAN | Details |
| T18 | Acetyl-CoA carboxylase 1 | ACACA | inhibitor | Enzyme | Q13085 | ACACA_HUMAN | Details |
| T20 | Fatty acid synthase | FASN | inhibitor | Enzyme | P49327 | FAS_HUMAN | Details |
| T07 | Bile acid receptor | NR1H4 | agonist | Nuclear hormone receptor | Q96RI1 | NR1H4_HUMAN | Details |
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I05 | 9352 | Type 2 diabetes mellitus | A diabetes that is characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both. A diabetes mellitus that is characterized by high blood sugar, insulin resistance, and relative lack of insulin. http://en.wikipedia.org/wiki/Diabetes, http://en.wikipedia.org/wiki/Diabetes_mellitus_type_2 | disease of metabolism/inherited metabolic disorder/ carbohydrate metabolic disorder/glucose metabolism disease/diabetes/ diabetes mellitus | Details |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress | |
|---|---|---|---|---|---|---|---|
| D225 | Metformin | Chemical drug | DB00331 | PRKAB1 inducer activator; ETEDH inhibitor; GPD1 inhibitor | Improve insulin resistance | Under clinical trials | Details |
| D142 | Fructose | Chemical drug | DB04173 | -- | Intravenous nutrition drug | Under clinical trials | Details |
| D401 | A mixture of Huangqi, Huanglian, Zexie, Yujin, Zhidahuang, Shanzha, Maiya, Zhizhi, Huangqin and Yincheng | Herbal medicine | -- | -- | -- | Under clinical trials | Details |
| D182 | Insulin | Biological drug | DB00030 | INSR agonist; CPE modulator&product of | -- | Under clinical trials | Details |
| D157 | Glucophage | Chemical drug | DB00331 | -- | -- | Under clinical trials | Details |